疟疾药物市场 - 全球产业规模、份额、趋势、机会及预测（按药物类型、药物剂型、最终用户、分销管道、地区和竞争格局划分，2021-2031年）

全球疟疾治疗市场预计将从 2025 年的 30.5 亿美元成长到 2031 年的 67.2 亿美元，年复合成长率为 14.07%。

该领域涵盖多种专业药物类别，例如以青蒿素为基础的联合疗法和预防药物，这些药物旨在治疗和预防疟疾原虫引起的感染疾病。市场成长的主要驱动力是全球持续存在的疟疾负担，这需要有效的治疗通讯协定和化学预防策略；此外，国际卫生组织和捐助机构的大力支持也进一步推动了市场发展，这些机构致力于优先保障疟疾流行地区的基本药物供应。世界卫生组织（世卫组织）估计，到2024年，全球将有2.82亿例疟疾病例，凸显了推动该产业发展的迫切公共卫生需求。

然而，市场成长面临一个重大障碍：抗疟疾药抗药性的日益增强。尤其是在疟疾高发生地区，已观察到对青蒿素衍生物的部分抗药性。这种生物适应性削弱了标准治疗方法的疗效，并迫使人们开发更复杂、更昂贵的治疗方法。这不仅威胁到现有价格适中的治疗方法的可行性，还造成了物流和财务方面的障碍，限制了下一代治疗方案的广泛商业性应用。

市场驱动因素

推动全球疟疾药物市场发展的关键因素之一是国际卫生组织资金的大幅成长，这些资金有效地补贴了基本抗疟疾药和预防性治疗的采购和分发。这笔资金注入对于弥合高昂的药物研发成本与流行地区低购买力之间的差距至关重要，确保新型治疗方法能够惠及患者群体。例如，2024年1月，全球基金核准了92亿美元的新津贴，用于加速2024年至2026年间对抗爱滋病、结核病和疟疾的进程。这些投资直接促进了干预策略的扩展，包括引入新一代医疗工具。因此，市场正迅速接受新的预防措施。 2024年12月，全球疫苗免疫联盟（Gavi）报告称，自疟疾疫苗引入以来，已采购并向流行地区交付了超过1,200万剂疟疾疫苗。

同时，疟疾高负担地区疟疾发病率的上升也推动了市场成长，而气候变迁和蚊虫栖息地的扩张加剧了这一趋势。环境变化导致疟疾感染季节延长，媒介传播疾病的病媒生物的地理分布范围扩大，使得需要紧急治疗的患者人数增加。这种持续的需求使得基于青蒿素的联合疗法和新兴替代疗法都保持着持续的商业性需求。近期流行病学数据凸显了这种需求的迫切性。 2024年12月，世界卫生组织（世卫组织）指出，预计2023年全球疟疾病例将比前一年增加约1,100万例，这再次强调了持续供应和治疗方法创新对于有效应对不断增长的患者数量的重要性。

市场挑战

抗疟疾药抗药性是限制全球疟疾治疗市场成长的主要障碍。这种生物演化正在逐步降低标准疗法的疗效，尤其是基于青蒿素的联合疗法，迫使製药开发商投入大量资金进行高风险的新化合物研发。以复杂的新一代分子取代现有的低成本学名药，造成了巨大的经济负担，并延长了研发週期。因此，市场面临生产力瓶颈，阻碍了经济实惠的解决方案的扩充性，给投资者带来不确定性，并延缓了对产生收入至关重要的重要新药的商业性部署。

此外，抗药性的蔓延需要严格且昂贵的监测机制来监测治疗效果，这会耗尽流行国家的医疗预算。这种经济压力减少了对先进疗法的投入，并限制了更新、更昂贵药物的市场渗透率。近期抗药性菌株传播的数据表明，这个问题十分严重。据世界卫生组织（世卫组织）称，到2024年，非洲区域至少有8个国家已确认或疑似对青蒿素衍生物的部分抗药性。这一趋势不仅威胁临床疗效，也造成了动盪的商业环境，迫使製造商不断调整以适应现有产品系列生命週期的缩短。

市场趋势

为规避标准青蒿素类药物普遍存在的抗药性问题，新型非青蒿素类药物的引入是一项重要的发展趋势。药物研发人员正优先研发具有不同作用机制的化合物，以确保对不断进化的寄生虫株具有持续的疗效。这种转变体现在新一代联合治疗的研发进展中，例如加那普拉西多-美芬特林，这类疗法旨在消除感染并阻断传播，而无需考虑青蒿素的敏感性。据诺华公司称，一项于2025年11月开展的针对这种新型非青蒿素候选药物的3期临床试验，在治疗非复杂性疟疾方面，经PCR校正的有效率达到了97.4%，达到了其主要终点，即疗效不劣于目前的标准疗法。

同时，儿童分散剂市场正在显着扩张，旨在提高儿童（最脆弱的患者群体）的治疗依从性和疗效。製造商正逐步放弃需要压碎的成人片剂，转而扩大可溶性、偏好製剂的生产规模，以确保儿童用药剂量准确。这种对儿童给药系统的关注，促使全球卫生伙伴关係支持大规模采购，以弥合疟疾流行国家的药物取得缺口。根据《疟疾药物与兽药》（MMV）报告显示，截至2025年4月，儿童治疗药物Coartem分散片的全球累积分发量已达到5亿剂，这凸显了该行业为降低五岁以下儿童死亡率而扩大生产规模的努力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球疟疾治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类型（青蒿素类联合疗法（ACT）、奎宁、Chloroquine、其他）
  • 依药物剂型（锭剂、胶囊、注射剂等）
  • 依最终使用者（成人、儿童、孕妇、其他）划分
  • 按分销管道（零售药局、医院、网路药局）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美疟疾药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲疟疾药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区疟疾药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲疟疾治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲疟疾药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球疟疾药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Novartis AG
• Sanofi SA
• Pfizer Inc
• GlaxoSmithKline Plc
• Merck & Co Inc
• F. Hoffmann-La Roche AG
• Cipla Limited
• Ajanta Pharma Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Malaria Therapeutics Market is projected to expand from a valuation of USD 3.05 Billion in 2025 to USD 6.72 Billion by 2031, reflecting a compound annual growth rate of 14.07%. This sector encompasses a specialized category of pharmaceutical agents, such as artemisinin-based combination therapies and prophylactic drugs, developed to treat and prevent infections caused by Plasmodium parasites. Market momentum is primarily sustained by the persistent global disease burden, which necessitates effective treatment protocols and chemoprevention strategies, further bolstered by strong backing from international health organizations and donor agencies focused on prioritizing access to essential medicines in endemic areas. Highlighting the urgent public health needs driving this industry, the World Health Organization estimated there were 282 million global malaria cases in 2024.

Conversely, market growth faces a substantial obstacle in the form of increasing antimalarial drug resistance, specifically partial resistance to artemisinin derivatives observed in high-burden territories. This biological adaptation undermines the effectiveness of standard-of-care regimens, requiring the creation of more intricate and expensive alternative treatments. As a result, the viability of existing affordable therapies is jeopardized, establishing logistical and financial barriers that limit the widespread commercial adoption of next-generation therapeutic solutions.

Market Driver

A primary factor accelerating the Global Malaria Therapeutics Market is the significant increase in funding from international health bodies, which effectively subsidizes the procurement and distribution of essential antimalarials and preventative treatments. This capital infusion is vital for bridging the gap between high drug development costs and the low purchasing power of endemic regions, ensuring that novel therapies reach patient populations. For example, The Global Fund approved US$9.2 billion in new grants in January 2024 to speed up the battle against HIV, tuberculosis, and malaria for the 2024-2026 period. Such investments directly facilitate the scaling of intervention strategies, including the deployment of next-generation medical tools. Consequently, the market is witnessing a rapid uptake of new preventive measures; Gavi, the Vaccine Alliance, reported in December 2024 that over 12 million malaria vaccine doses had been procured and shipped to endemic countries since the rollout began.

Concurrently, the market is expanding due to the rising incidence of malaria in high-burden regions, a trend exacerbated by climate change and widening mosquito habitats. Environmental shifts are prolonging transmission seasons and expanding the geographical range of vectors, thereby raising the volume of patients requiring immediate therapeutic intervention. This persistent demand generates a sustained commercial requirement for both artemisinin-based combination therapies and emerging alternative drugs. The urgency of this demand is highlighted by recent epidemiological data; the World Health Organization noted in December 2024 that global malaria cases rose by approximately 11 million in 2023 compared to the prior year, reinforcing the critical need for continuous supply and innovation in therapeutic regimens to manage the growing patient load effectively.

Market Challenge

Antimalarial drug resistance constitutes a major hurdle significantly restricting the growth of the global malaria therapeutics market. This biological evolution renders standard-of-care treatments, specifically artemisinin-based combination therapies, increasingly ineffective, compelling pharmaceutical developers to redirect significant capital toward the high-risk discovery of novel compounds. The necessity to replace established, low-cost generics with complex next-generation molecules creates severe financial strain and extends research timelines. Consequently, the market encounters a productivity bottleneck where the scalability of affordable solutions is compromised, generating uncertainty for investors and delaying the commercial rollout of essential new medicines that are vital for revenue generation.

Furthermore, the proliferation of resistance necessitates rigorous and expensive surveillance mechanisms to monitor therapeutic efficacy, thereby draining healthcare budgets in endemic nations. This economic pressure reduces the available funds for purchasing advanced therapeutics, limiting the market penetration of newer, higher-priced drugs. The magnitude of this issue is evident in recent data regarding the spread of resistant strains; according to the World Health Organization, in 2024, partial resistance to artemisinin derivatives was confirmed or suspected in at least eight countries within the African region. This trend not only threatens clinical outcomes but also creates a volatile commercial environment where manufacturers must constantly adapt to the diminishing lifespan of their existing product portfolios.

Market Trends

The introduction of novel non-artemisinin drug classes constitutes a critical trend aimed at circumventing the widespread issue of partial resistance to standard artemisinin-based therapies. Pharmaceutical developers are prioritizing compounds with alternative mechanisms of action to ensure continued therapeutic efficacy against evolving parasite strains. This shift is exemplified by the advancement of next-generation combinations such as ganaplacide-lumefantrine, which are designed to clear infections independent of artemisinin susceptibility and block transmission. According to Novartis, in November 2025, the Phase 3 clinical trial for this novel non-artemisinin candidate achieved a PCR-corrected efficacy of 97.4% in treating uncomplicated malaria, meeting the primary endpoint of non-inferiority to current standards.

Simultaneously, the market is experiencing a significant expansion of pediatric-specific dispersible formulations intended to improve treatment adherence and outcomes among the most vulnerable patient demographic. Manufacturers are increasingly moving away from adult tablets that require crushing, instead scaling the production of soluble, palatable options that ensure accurate dosing for children. This focus on child-friendly delivery systems has led to massive procurement volumes supported by global health partnerships to bridge the access gap in endemic countries. According to Medicines for Malaria Venture, in April 2025, the cumulative global distribution of the pediatric treatment Coartem Dispersible reached a landmark 500 million courses, underscoring the industrial scale-up dedicated to reducing mortality in children under five.

Key Market Players

• Novartis AG
• Sanofi S.A
• Pfizer Inc
• GlaxoSmithKline Plc
• Merck & Co Inc
• F. Hoffmann-La Roche AG
• Cipla Limited
• Ajanta Pharma Limited

Report Scope

In this report, the Global Malaria Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malaria Therapeutics Market, By Drug Type

• Artemisinin-based combination therapy (ACT)
• Quinine
• Chloroquine
• Others

Malaria Therapeutics Market, By Drug Formulation

• Tablets
• Capsules
• Injectables
• Others

Malaria Therapeutics Market, By End User

• Adults
• Children
• Pregnant Women
• Others

Malaria Therapeutics Market, By Distribution Channel

• Retail pharmacies
• Hospitals
• Online pharmacies

Malaria Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malaria Therapeutics Market.

Available Customizations:

Global Malaria Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malaria Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Artemisinin-based combination therapy (ACT), Quinine, Chloroquine, Others)
  • 5.2.2. By Drug Formulation (Tablets, Capsules, Injectables, Others)
  • 5.2.3. By End User (Adults, Children, Pregnant Women, Others)
  • 5.2.4. By Distribution Channel (Retail pharmacies, Hospitals, Online pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Malaria Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Drug Formulation
  • 6.2.3. By End User
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Malaria Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Drug Formulation
      • 6.3.1.2.3. By End User
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Malaria Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Drug Formulation
      • 6.3.2.2.3. By End User
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Malaria Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Drug Formulation
      • 6.3.3.2.3. By End User
      • 6.3.3.2.4. By Distribution Channel

7. Europe Malaria Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Drug Formulation
  • 7.2.3. By End User
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Malaria Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Drug Formulation
      • 7.3.1.2.3. By End User
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Malaria Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Drug Formulation
      • 7.3.2.2.3. By End User
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Malaria Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Drug Formulation
      • 7.3.3.2.3. By End User
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Malaria Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Drug Formulation
      • 7.3.4.2.3. By End User
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Malaria Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Drug Formulation
      • 7.3.5.2.3. By End User
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Malaria Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Drug Formulation
  • 8.2.3. By End User
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Malaria Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Drug Formulation
      • 8.3.1.2.3. By End User
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Malaria Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Drug Formulation
      • 8.3.2.2.3. By End User
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Malaria Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Drug Formulation
      • 8.3.3.2.3. By End User
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Malaria Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Drug Formulation
      • 8.3.4.2.3. By End User
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Malaria Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Drug Formulation
      • 8.3.5.2.3. By End User
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Malaria Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Drug Formulation
  • 9.2.3. By End User
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Malaria Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Drug Formulation
      • 9.3.1.2.3. By End User
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Malaria Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Drug Formulation
      • 9.3.2.2.3. By End User
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Malaria Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Drug Formulation
      • 9.3.3.2.3. By End User
      • 9.3.3.2.4. By Distribution Channel

10. South America Malaria Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Drug Formulation
  • 10.2.3. By End User
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Malaria Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Drug Formulation
      • 10.3.1.2.3. By End User
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Malaria Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Drug Formulation
      • 10.3.2.2.3. By End User
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Malaria Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Drug Formulation
      • 10.3.3.2.3. By End User
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Malaria Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi S.A
• 15.3. Pfizer Inc
• 15.4. GlaxoSmithKline Plc
• 15.5. Merck & Co Inc
• 15.6. F. Hoffmann-La Roche AG
• 15.7. Cipla Limited
• 15.8. Ajanta Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer